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We have characterized envelope protein pseudotyped HIV-2 particles derived from two HIV-2 isolates termed prCBL23 and CBL23 in
order to define the role of the envelope protein for the Lv2-mediated restriction to infection. Previously, it has been described that the primary
isolate prCBL23 is restricted to infection of several human cell types, whereas the T cell line adapted isolate CBL23 is not restricted in these
cell types. Molecular cloning of the two isolates revealed that the env and the gag gene are responsible for the observed phenotype and that
this restriction is mediated by Lv2, which is distinct from Ref1/Lv1 (Schmitz, C., Marchant, D., Neil, S.J., Aubin, K., Reuter, S., Dittmar,
M.T., McKnight, A., Kizhatil, K., Albritton, L.M., 2004. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J. Virol.
78 (4), 2006–2016).
We generated pseudotyped viruses consisting of HIV-2 (ROD-ADenv-GFP, ROD-ADenv-RFP, or ROD-ADenv-REN) and the prCBL23
or CBL23 envelope proteins as well as chimeric proteins between these envelopes. We demonstrate that a single amino acid exchange at
position 74 in the surface unit of CBL23-Env confers restriction to infection. This single point mutation causes tighter CD4 binding, resulting
in a less efficient fusion into the cytosol of the restricted cell line. Prevention of endosome formation and prevention of endosome
acidification enhance infectivity of the restricted particles for GHOST/X4 cells indicating a degradative lysosomal pathway as a cause for the
reduced cytosolic entry. The described restriction to infection of the primary isolate prCBL23 is therefore largely caused by an entry defect. A
remaining restriction to infection (19-fold) is preserved when endosomal acidification is prevented. This restriction to infection is also
dependent on the presence of the point mutation at position 74 (G74E).
D 2004 Elsevier Inc. All rights reserved.
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Early steps of the replication cycle of the human
immunodeficiency virus have been at the center of attention
since the discovery of the HIV co-receptors and the
elucidation of the molecular basis of transmembrane protein
mediated virus–cell fusion (Berger et al., 1999; Clapham
and McKnight, 2002). The interaction of the surface unit of
the viral envelope protein of HIV with CD4 and a
chemokine receptor leads to the insertion of the fusion
peptide into the target cell membrane. This peptide is part of
the transmembrane protein of the viral envelope, which
facilitates, through conserved helical structures (HR1 and0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(M.T. Dittmar).HR2), the formation of a fusion pore to allow the viral core
to enter the cytoplasm (for review, see Eckert and Kim,
2001). After exposure of the viral core inside the cell, only
limited information is available about the processes result-
ing in successful integration of the proviral genome. Such
post-entry events include the release of the viral RNA
genome from the core, formation of the pre-integration
complex (PIC), initiation of reverse transcription, and
transport of the proviral genome to the nucleus.
Although these post-entry steps in the replication cycle
have been biochemically defined, a clear understanding of
these processes is only slowly emerging (for review, see
Dvorin and Malim, 2003). Due to the apparent instability of
the viral core, it is believed that this structure disassembles
shortly after being released into the cytoplasm followed by
the formation of the pre-integration complex. Whether the
initiation of reverse transcription takes place inside the core05) 347–358
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RNA, reverse transcriptase, integrase, and several other viral
and cellular proteins have been implicated to be part of this
complex (Greene and Peterlin, 2002). Because of the high
viscosity of the cytoplasm, movement of the PIC by
diffusion is very limited. The microtuble network and
dynein are implicated as the cellular structures that facilitate
movement of the PIC towards the nucleus (McDonald et al.,
2002).
A number of cellular host factors that interfere with early
steps of the retroviral replication process have been
identified. For example, actin microfilaments have been
implicated in the formation of PIC (Bukrinskaya et al.,
1998). Furthermore, the product of the murine Fv-1 gene, a
derivative of an murine endogenous retroviral gag gene,
limits the replication of certain murine leukemia virus
strains (Best et al., 1996) in rodent cell lines and is therefore
by definition a restriction factor. Human and monkey cell
lines express a factor, called Ref1/Lv1, which restricts N-
MLV and other retroviruses. Such restriction factors in
primate cells target the viral capsid proteins prior to
initiation or completion of the reverse transcription (Stoye,
2002; Towers et al., 2000).
Recently, Stremlau et al. (2004) characterized a member
of the TRIM family as a restriction factor active in primate
cells. Overexpression of TRIM5a in HeLa/CD4 cells results
in substantial decrease of infection of HIV-1 when the
TRIM5a variant from rhesus macaques was introduced.
TRIM5a from African Green Monkeys constitutes a
restriction factor as well (Hatziioannou et al., 2004;
Keckesova et al., 2004; Perron et al., 2004; Yap et al.,
2004). The human homologue showed only weak activity.
Most of those studies to characterize Ref1/Lv1 and similar
factors have been conducted using VSV-G envelope
pseudotyped particles; therefore, Ref1/Lv1 restriction is
independent of the route of viral entry. We have shown
previously that Lv2, which is distinct from Ref1/Lv1, acts at
earlier steps of the viral life cycle and is overcome with
VSV-G pseudotyped HIV-2 isolates (McKnight et al., 2001;
Schmitz et al., 2004).
The initial interaction of the viral envelope with the entry
receptors or other surface structures primes the target cell to
facilitate successful integration. Mori et al. (1993) observed
that the envelope protein restricted the replication of a
certain SIV strain in macrophages at a post entry step.
Likewise, the infection of human macrophages by X4-tropic
HIV-1 strains has been shown to be restricted at a post-entry
level post-reverse transcription (Schmidtmayerova et al.,
1998; Verani et al., 1998). Furthermore, a correlation
between the capacity of a CCR5-tropic envelope protein
to induce signals through CCR5 and the replication in
macrophages has been described (Arthos et al., 2000).
CCR5-tropic viruses activate MEK/ERK, as well as JNK
and p38 MAPKs (Popik and Pitha, 2000a). Similarly,
interaction of CXCR4 tropic isolates with CXCR4 on target
cells activates the MEK/ERK pathway, at least for certaincell lines (Kinet et al., 2002). Ultimately, such signals may
facilitate reverse transcription and integration, steps of the
HIV replication cycle that are known to depend on the state
of cell activation (Alfano et al., 1999, 2000; Arthos et al.,
2000; Cicala et al., 1999; Liu et al., 2000) and may be linked
to the inhibitory function of restriction factor(s).
Here, we analyzed the role of the envelope protein of a
primary HIV-2 isolate for the restriction to infection of
human cells. We demonstrate that a single amino acid
exchange at position 74 in the surface unit of CBL23-Env
confers restriction to infection. This single point mutation
causes tighter CD4 binding resulting in a less efficient
fusion into the cytosol of the restricted cell line. Prevention
of endosome formation and prevention of endosome acid-
ification enhance infectivity of the restricted particles for
GHOST/X4 cells, indicating a degradative lysosomal path-
way as a cause for the reduced cytosolic entry. The
described restriction to infection of the primary isolate
prCBL23 (McKnight et al., 2001; Schmitz et al., 2004) is
therefore largely caused by an entry defect. However, a
remaining restriction to infection (19 fold) is preserved
when endosomal acidification is prevented. This restriction
to infection is also dependent on the presence of the point
mutation at position 74 (G74E) and could therefore, together
with the capsid dependent restriction to infection, account
for the LV2-mediated restriction in human cells.Results
HIV-2 envelope pseudotyped HIV-2 particles confirm the
envelope-dependent restriction to infection of GHOST-X4
cells
Molecular clones derived from the isolate prCBL23
encode for a premature stop codon in the envelope
glycoprotein, resulting in a truncated cytoplasmic tail of
the transmembrane protein gp35 compared to the full-length
envelope of CBL23 (Schmitz et al., 2004). In order to
compare the envelope genes of both virus isolates, HIV-2
reporter vectors were constructed, which do not express the
envelope gene and contain a reporter gene (EGFP, mRFP, or
renilla luciferase, respectively) instead of the HIV-2 nef
gene (Fig. 1A). These reporter vectors were used to generate
pseudotyped virus particles containing the envelope proteins
of prCBL23 and CBL23 respectively. This was achieved
after cloning recombinant envelope genes into the murine
retroviral expression vector MP11 to obtain high levels of
envelope protein production after co-transfection.
The first set of studied recombinant env-expression
vectors (Fig. 1B) encoded the parental prCBL23 and
CBL23 envelopes (Env35 and Env42) and a variant of
prCBL23, in which the premature stop codon was mutated
to the amino acid tryptophan (present in CBL23: Env35R2).
Additionally, a truncated envelope of CBL23 with a stop
codon at position 742 was constructed (Env42S).
Fig. 2. Mapping the envelope molecular determinants responsible for the restrictio
stocks carrying the envelope proteins indicated were used to infect U87/CD4/X4 ce
and the number of infected cells per infection was calculated (left and middle p
compared to that on GHOST/X4 cells with error bars calculated from the results o
obtained from the infection with HIV-2[Env42] was arbitrarily set to 1 (for calcu
Fig. 1. Schematic representation of the envelope-minus reporter vectors and
envelope proteins used to examine the role of the HIV-2 envelope in the
Lv2-mediated restriction to infection. (A) The vector ROD-ADenv was
constructed using the ROD-A molecular clone ACR23 through deletion of
the first eight amino acids of the env ORF (black bar). Fusion PCR was
used to replace large parts of the nef open reading frame by the coding
region of the green fluorescent protein, red fluorescent protein and renilla
luciferase, resulting in ROD-ADenv-GFP, ROD-ADenv-RFP and ROD-
ADenv-REN, respectively. (B) Schematic representation of the envelope
constructs used to define the region of the outer envelope responsible for
the restriction to infection of GHOST/X4 cells. Shown are the two wild-
type envelope proteins (prCBL23 = Env35 and CBL23 = Env42), the set of
truncated or restored cytoplasmic tails of gp35 (Env35R2 and Env42S), and
envelope proteins with point mutations at position 74 and 111 (Env53S) and
position 74 only (Env42S-G74E, Env35-E74G). Bold letters indicate amino
acid differences between the envelope proteins (gray = restricted; black =
nonrestricted envelope proteins).
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prCBL23 isolate on the two cell lines U87/CD4/X4 and
GHOST/X4 shows a restriction to infection in comparison
to CBL23. The isolate CBL23 is not restricted to infection
in GHOST/X4 cells, and therefore the calculated ratio of
infectious titres (U87/CD4/X4 vs. GHOST/X4) was set to
1 (McKnight et al., 2001; Schmitz et al., 2004). The
pseudotyped HIV-2 particles, which had incorporated
envelope proteins of prCBL23 (Env35, Env35R2) or
CBL23 (Env42, Env42S), respectively, were used to infect
both cell lines and the viral titres were determined. As
Fig. 2 demonstrates, the infection of U87/CD4/X4 cells
resulted in titres between 3  103 and 1  105 FFU/ml,
depending on the HIV-2 pseudotype used (Fig. 2, left).
The infection of GHOST/X4 cells resulted in infectious
titres between 1  102 and 8  104 FFU/ml (Fig. 2,
middle). The calculated ratio of infectious titres between
both cell lines revealed that pseudotyped particles with
incorporated Env35 displayed a 58-fold restriction to
infection in comparison to the HIV-2[Env42] particles
(Fig. 2, right panel). This 58-fold restriction was com-
parable to the fold restriction described before (McKnight
et al., 2001; Schmitz et al., 2004). The truncation of the
cytoplasmic tail in the CBL23 derived envelope (Env42S)
did not result in a restriction to infection, whereas the
restoration of a full-length cytoplasmic tail in the
prCBL23 envelope (Env35R2) maintained the restriction,
although at a reduced level (14-fold). Thus, envelope
pseudotyped HIV-2 particles confirm the envelope-
dependent restriction to infection and allow further
analysis of the envelope region(s) responsible for this
phenotype.
Since the truncation of the cytoplasmic tail does not
cause a restriction to infection (HIV-2[Env42S]), we
reasoned that a region in gp125, the surface unit (SU), is
important for the restriction. To define precisely the
envelope region(s) responsible for the restriction to infec-
tion of GHOST/X4 cells, several chimeric envelope
expression plasmids were constructed and pseutotyped
particles generated. Using the expression plasmid forn to infection in GHOST/X4 cells. Equal volumes of pseudotyped particle
lls and GHOST/X4 cells. After 2 days, the cells were fixed, immunostained
anel). Fold restriction refers to the infectious titres on U87/CD4/X4 cells
f three independent experiments (right panel). The ratio of infectious titres
lation, see Materials and methods and Schmitz et al., 2004).
Fig. 3. Restricted pseudotyped particles display higher CD4 binding. (A)
Sensitivity of pseudotyped HIV-2 particles to anti-CD4 antibody-mediated
inhibition. U87/CD4/X4 and GHOST/X4 cells were pretreated for 30 min
at 37 8C with anti-CD4 antibody at different concentrations (5, 1, 0.2, 0.04,
and 0.002 Ag of anti-CD4 antibody/ml) before adding equal amounts of
pseudotyped particles (5 ng RT-equivalent). The cells were lysed at 2 days
post-infection and the renilla luciferase activity (expressed due to infection
with ROD-ADenv-REN derived particles) was measured. Relative infection
(% of control) was calculated by dividing the mean number of relative light
units at each anti-CD4 antibody concentration by the mean number of
relative light units from cells containing no antibody and is shown on the y-
axis. The anti-CD4 antibody concentration is shown on the x-axis.
Duplicate wells were analyzed for each drug concentration in at least three
independent experiments. (B) Transiently transfected 293T cells expressing
no CD4 or truncated CD4 (CD4-cyt399) were incubated with pseudotyped
particles containing a mRFP-vpr2 fusion protein and the envelope proteins
indicated. After incubation of particles with 293T cells (1 h at 37 8C),
nonbound particles were removed and bound particles quantitated by
detection of particle associated red fluorescence at 508 nm. As controls,
envelope-deficient particles and particles pseudotyped with the envelope
protein of GALV were used. The higher the fluorescence ratio (dividing the
fluorescence obtained from 293T-CD4-cyt399 cells by the fluorescence
obtained from mock transfected 293T cells), the stronger the CD4-
dependent binding. Data are representative of results obtained in two
independent experiments.
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and Env53S was generated. In addition, the amino acid at
position 74 in Env42S was mutated to generate Env42S–
G74E as well as the reverse mutation in the expression
plasmid for Env35, resulting in Env35–E74G (Fig. 1B).
These three chimeric envelope proteins were used to
generate pseudotyped HIV-2 particles and the ratio of
infectious titres for U87/CD4/X4 and GHOST/X4 was
determined. Fig. 2 clearly indicates that the restriction to
infection is conferred by the 5V end of gp125. HIV-
2[Env53S] particles showed a 55-fold restriction in com-
parison to HIV-2[Env42S] or HIV-2[Env42] particles. HIV-
2[Env42S-G74E] particles showed a less pronounced but
still substantial restriction to infection (20-fold). Pseudo-
typed particles with incorporated envelopes encoding the
reverse mutation in the Env35 backbone, HIV-2[Env35-
E74G], did not show the restriction to infection, as observed
for the wild-type envelope Env35, thereby confirming the
importance of amino acid 74 for the restriction. In addition,
a mutation at position 111 in Env42S did not cause a
restriction to infection and the reverse mutation in the
prCBL23 envelope (Env35) did not abrogate the restriction
to infection (data not shown).
HIV-2 entry route for GHOST/X4 cells differs between
restricted and nonrestricted pseudotyped particles
Next, we determined the CD4 dependence of these
pseudotyped particles using an anti-CD4 antibody to
neutralize infection. Fig. 3A shows the inhibition of
infection of the pseudotyped particles expressing different
chimeric HIV-2 envelopes and HIV-2[VSV-G] particles. For
these assays, the renilla luciferase encoding ROD-ADenv-
REN vector was used to generate pseudotyped particles.
Infection in the absence of anti-CD4 antibody was set to
100% and relative infection in the presence of increasing
concentrations of anti-CD4 antibody is depicted for both
cell lines. This experiment showed that all viruses were
equally well neutralized by anti-CD4 antibody when U87/
CD4/X4 cells were used as target cells. However, the
inhibition of infection by anti-CD4 antibody showed
striking differences when GHOST/X4 cells were used. Only
the nonrestricted particles HIV-2[Env42S] and HIV-
2[Env35-E74G] were efficiently neutralized by anti-CD4
antibody. To reach a 50% inhibition of infection, a 4-fold
higher concentration of anti-CD4 antibody was needed
compared to U87/CD4/X4 cells, despite a lower steady state
level of surface CD4 for GHOST/X4 cells as detected by
FACS (data not shown). The restricted particles, carrying
the envelopes Env35, Env53S, and Env42S-G74E, were 10-
fold resistant to inhibition by anti-CD4 antibody compared
to HIV-2[Env42S], indicating a stronger interaction of
restricted envelope proteins with CD4 compared to the
nonrestricted envelope protein Env42S. For both cell lines,
the infection by HIV-2[VSV-G] was unaffected by the
presence of anti-CD4 antibody.In order to address the envelope-CD4 binding in another
system, we transiently transfected 293T cells with an
expression plasmid encoding for a cytoplasmic tail truncated
CD4 molecule. Tail-truncated CD4 (CD4-cyt399) is not
endocytosed and remains at the cell surface, but supports
HIV entry in the presence of the appropriate coreceptor
(Bedinger et al., 1988; Maddon et al., 1988; Pelchen-
Matthews et al., 1995). Incubation of mock-transfected or
CD4-cyt399-transfected 293T cells with equal amounts of
pseudotyped particles containing the mRFP-vpr2 fusion
protein results in binding of particles to 293T cells depend-
ent on the presence of CD4 alone. Quantitation of particle
binding is possible due to the particle associated mRFP-vpr2
fusion proteins using a microplate fluorometer. As Fig. 3B
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or the envelope protein of Gibbon Ape Leukemia Virus
(GALV) do not specifically bind to CD4-cyt399 (fluores-
cence ratio for 293T-CD4cyt399 cells vs. 293T cells around
or below 1). The two restricted particles, HIV-2[Env35] and
HIV-2[Env42-G74E], however, display a stronger CD4
binding capacity when compared to the nonrestricted
particles HIV-2[Env42S] and HIV-2[Env35-E74G]. This
result supports the initial notion that restricted particles bind
tighter to CD4 than nonrestricted particles.
Next, we determined the virus–cell fusion efficiency of
the restricted and nonrestricted particles. We made use of the
recently described virion-based fusion assay (Cavrois et al.,
2002; Lineberger et al., 2002) that measures cytosolic
delivery of h-lactamase (BlaM) from virions into target
cells. This assay has been shown to discriminate between
fusion and endocytosis of virions due to the lack of CCF2/
AM availability within endosomes (Cavrois et al., 2002;
Schaeffer et al., 2004). Pseudotyped particles, which
incorporated a fusion protein of BlaMDvpr2 were generated
and used to infect U87/CD4/X4 and GHOST/X4 cells.
Equal multiplicity of infection were used and after 3 h the
cells were loaded with CCF2/AM for 18 h at room
temperature. The fluorescence was measured in a microplate
fluorometer. Fluorescence ratios were calculated after
subtraction of background fluorescence of control cultures
containing no virus. The results of triplicate values for both
cell types are depicted in Fig. 4. As expected, the infection
with envelope minus particles did not result in increasing
fluorescence at 447 nm for either cell line. The infection of
U87/CD4/X4 cells showed no significant differences
between restricted and nonrestricted HIV-2 particles,
although HIV-2[Env35R2] infection of U87/CD4/X4 cells
resulted repeatedly in a lower fluorescence ratio. The
infection of GHOST/X4 with the nonrestricted pseudotyped
particles HIV-2[Env42] and HIV-2[Env42S] resulted in a
significantly higher fluorescence at 447 nm when compared
to the restricted pseudotyped particles, indicating a higher
efficiency in reaching the cytoplasm. To analyze the fold
restriction to fusion, we divided the fluorescence ratio
obtained from the BlaM-assay for U87/CD4/X4 cells by theFig. 4. Virus to cell fusion assay confirms reduced cytosolic entry for restricted part
G74E) and nonrestricted particles (Env42, Env42S) were assayed for fusion with
reporter assay. Data shown are mean of triplicate determinations and are represent
were used as negative controls. The fluorescence ratio (447 vs. 520 nm) is shown o
dividing these fluorescence ratios obtained from U87/CD4/X4 cells and GHOSTfluorescence ratio obtained from the BlaM-assay for
GHOST/X4 cells. Fig. 4 (right panel) illustrates that the
restricted envelope proteins Env35, Env53S, and Env42-
G74E were 2.5- to 3-fold less efficient for virus entry when
compared to the nonrestricted envelope proteins Env42,
Env42S, and Env35E74G.
We hypothesized that the determined strong CD4
interaction and reduced viral entry could be reconciled by
differences in endosomal uptake of bound particles by
GHOST/X4 cells and subsequent degradation in lysosomes.
Therefore, we determined the basal endocytosis rate of CD4
for U87/CD4/X4 cells and GHOST/X4 cells. Fig. 5A shows
the result of the kinetic endocytosis assay performed. CD4
internalization from the cell surface does not differ between
the two cell lines. After 40 min, 48% (U87/CD4/X4 cells)
and 53% (GHOST/X4 cells) of the marked CD4 molecules
remain at the cell surface. Since this assay does not measure
a potential virus-induced CD4 internalization, we next
studied the infectivity of restricted and nonrestricted
particles depending on the presence of ammonium chloride
(NH4Cl), a lysomotropic weak base that prevents endosome
and lysosome acidification. As has been described earlier,
pre-incubation of target cells with NH4Cl enhances HIV-1
infectivity in HeLa cells (Aiken, 1997). U87/CD4/X4 cells
and GHOST/X4 cells were pre-incubated with NH4Cl and
subsequently infected using the pseudotyped particles HIV-
2[Env35] and HIV-2[Env42S]. As Fig. 5B shows, the
concentration of NH4Cl used (10 mM) was sufficient to
abrogate VSV-G mediated infection. Again, the direct
comparison of restricted and nonrestricted particles revealed
differences for the GHOST/X4 cells and not for U87/CD4/
X4 cells. Pre-treatment with NH4Cl caused a 10-fold
increase of infectivity of the restricted HIV-2[Env35], and
only a modest 1.4-fold increase for the nonrestricted HIV-
2[Env42]. The infectivity on U87/CD4/X4 cells was less
dependent on the NH4Cl treatment for both pseudotyped
particles, 1.9- and 0.8-fold, respectively.
In order to test endosomal uptake more directly, GHOST/
X4 cells were transfected with dynamin and dynaminK44A
expression plasmids. Both proteins were expressed as GFP-
fusion proteins allowing quantification of the transfectionicles. Restricted pseudotyped particles (Env35, Env35R2, Env53S, Env42S-
U87/CD4/X4 cells (left) and GHOST/X4 cells (middle) in the BlaM-Vpr2
ative of at least three independent experiments. Envelope-negative particles
n the y-axis. Fold restriction of fusion into the cytoplasm was determined by
/X4 cells (right panel).
Fig. 5. Basal endocytosis of CD4 and endosomal uptake of particles. (A) Rate of CD4 endocytosis was analyzed for U87/CD4/X4 cells and GHOST/X4 cells
over time. CD4 internalization from the cell surface is equally efficient for both cell lines. (B) Inhibition of endosomal acidification: For the inhibition of
endosomal acidification, both cell lines were pretreated with NH4Cl (10 mM) for 30 min at 37 8C before adding equal amounts of infectious virus (ROD-
ADenv-derived particles). The cells were immunostained 2 days post-infection and the number of blue cells determined. HIV-2[VSV-G] particles were used to
control for complete inhibition of acidification of endosomes. (C) Relative infectivity of ROD-ADenvRFP-derived particles after challenge of dynamin or
dynaminK44A transfected GHOST/X4 cells. Forty-eight hours post-infection, red fluorescence at 607 nm and green fluorescence at 508 nm were determined.
The ratio of red fluorescence versus green fluorescence allows the quantification of infectivity of the respective pseudotyped particles dependent on the
expression of the GFP-dynamin fusion proteins. One representative experiment out of three is shown. (D) Fold restriction was determined by dividing the
infectious titres obtained from U87/CD4/X4 cells and GHOST/X4 cells (results from experiment B) in the absence of NH4Cl and in the presence of 10 mM
NH4Cl, respectively.
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been shown to abrogate endosome formation (van der Bliek
et al., 1993). Therefore, after challenge with HIV-2[Env35]
pseudotyped particles, we expected an increase in infectivity
and a decrease in infectivity for HIV-2[VSV-G] pseudo-
typed particles. Transiently transfected GHOST/X4 cells
were seeded into 48-well trays and subsequently infected
using ROD-ADenvRFP derived pseudotyped particles HIV-
2[Env35], HIV-2[Env42S], and HIV-2[VSV-G], respec-
tively. Forty-eight hours post-infection, the total red
fluorescence (infected cells) and green fluorescence (trans-
fected cells) was determined. The transfection resulted in
only 25% dynamin-expressing GHOST/X4 cells (data not
shown). As Fig. 5C shows, this low transfection efficiency
resulted nevertheless in a modest increase in infectivity for
HIV-2[Env35] particles (11%) and a modest decrease in
infectivity of HIV-2[VSV-G] particles (21%), supporting
our hypothesis of endosomal uptake.However, even after blocking endosomal acidification
(Fig. 5B), a 19-fold restriction to infection in GHOST/X4
cells was observed (Fig. 5D). Since endosomal uptake has
been shown to circumvent Lv2-mediated restriction
(McKnight et al., 2001), the remaining restriction to
infection could be a result of divergent entry pathways
from distinct plasma membrane structures as initially
proposed.
Stimulation of MAPK after particle binding
Since it has been shown that envelope–receptor inter-
action can result in the induction of the MAPK cascade
(Popik and Pitha, 2000a), we also tested whether the
restricted and nonrestricted envelope proteins of HIV-2
induce different intracellular signals upon binding to
GHOST/X4 cells, thereby accounting for enhanced CD4
endocytosis. Serum-depleted cells were incubated with
Fig. 6. Stimulation of p44/p42 MAPK by restricted and nonrestricted
pseudotyped particles is equally efficient. GHOST/X4 cells were incubated
with particle preparations (100 ng RT equivalents) carrying no envelope,
Env35, Env42S, 200 ng/ml anisomycin or 10% FCS in the presence or
absence of 50 AM UO126 for 30 min at 37 8C. Detection of p44/p42
MAPK, SAPK/JNK, and p38-MAPK was performed using the phospho-
MAPK family antibody sampler kit. Blots were reprobed with anti-14-3-3g
to assure equivalent loading in each lane. Data are representative of results
obtained in two independent experiments.
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HIV-2[Env42S]) as well as 10% FCS or anisomycin, an
activator for all three MAPK family members studied.
Serum depletion resulted in a complete reduction of
ppSAPK/JNK and pp38 MAPK, whereas some pp44/pp42
MAPK remained detectable. The MEK1/2 inhibitor UO126
was used to specifically block the activation of ERK1/2.
After 30-min incubation with the different particles, the cells
were lysed and immunoblotted. As Fig. 6 shows, the
incubation of GHOST/X4 cells with a high concentration
of FCS (10%) and with anisomycin (200 ng/ml) resulted in a
substantial increase of activated p44/p42 MAPK. The
incubation with UO126 inhibited this activation effectively.
The incubation of GHOST/X4 cells with envelope-minus
particles or particles carrying the restricted (Env35) or
nonrestricted (Env42S) envelope proteins stimulated p44/
p42 MAPK equally efficient and this stimulation was also
blocked by UO126. For SAPK/JNK and p38-MAPK,
stimulation was detected due to incubation with anisomycin
(and was not blocked by UO126) but not due to incubation
with pseudotyped particles. An ELISA-based quantitative
analysis of ERK1/2 activity confirmed the results of the
western blot analysis (data not shown). Therefore, a
differential stimulation of MAPK family members cannot
explain the differences in viral uptake observed for the HIV-
2[Env35] pseudotyped particles.Discussion
This study localizes a critical region in the envelope
protein of the isolate prCBL23 that can alter entry events in
the viral life cycle and refines a previously described
restriction to infection of human cells by this HIV-2 isolate
(McKnight et al., 2001; Schmitz et al., 2004). We employeda HIV-2ROD-derived, envelope gene deleted vector as
backbone pseudotyped with envelope proteins derived from
CBL23 and prCBL23. This has allowed us to study the role
of the envelope proteins of CBL23 and prCBL23 independ-
ently of potential interactions of the capsid protein also
shown to mediate post-entry restrictions (Schmitz et al.,
2004). After analyzing a large set of chimeric envelope
proteins, including single point mutations, we can conclude
from the immunostaining experiments (Fig. 2) that the
amino acid at position 74 (N-terminal of the V1 region) is
responsible for the restriction to infection of GHOST/X4
cells.
It has been shown that receptor cell surface density is
involved in infectivity of macrophages, thymocytes, and cell
lines (Naif et al., 1998; Pedroza-Martins et al., 1998; Platt et
al., 1998) and that certain envelope proteins have higher
affinities to the corresponding receptors (for review, see
Clapham and McKnight, 2002). We have performed assays
to address the CD4 dependence of the restricted and
nonrestricted envelope proteins. The amino acid exchange
at position 74 does not result in CD4-independence, since
for all chimeric envelope proteins studied, the IC50 values
obtained from the inhibition of U87/CD4/X4 infection are
comparable. Although GHOST/X4 cells display lower
steady state levels of CD4 on their cell surface, larger
amounts of anti-CD4 antibody was required to inhibit
infection compared to U87/CD4/X4 cells. Moreover, despite
the high concentration of anti-CD4 antibody used, the
restricted particles carrying the envelope proteins Env35,
Env53S, Env42S–G74E were not inhibited on GHOST/X4
cells, indicating a tighter gp125–CD4 interaction. This
interpretation is supported by a particle binding assay
(Fig. 3B) using transiently transfected 293T cells expressing
cytoplasmic tail deleted CD4.
The results of the virus–cell fusion assay revealed that
restricted particles are less efficient in fusion into the
cytosol, since only the delivery of active BlaM into the
cytosol results in cleavage of the fluorescent dye CCF2/AM
(Fig. 4). Prevention of endosomal acidification resulted in
enhanced infectivity for all pseudotyped particles examined,
and this was more pronounced for the restricted particles
carrying envelope protein Env35 (Fig. 5B). It has been
shown that NH4Cl treatment enhances entry via the fusion
pathway for HIV-1 (Pelchen-Matthews et al., 1995;
Schaeffer et al., 2004). Our studies confirm and extend
this finding also reported by others (Fackler and Peterlin,
2000; Marechal et al., 2001) now including HIV-2. More-
over, transiently expressed dominant-negative dynamin
(dynK44A) causes an increase in infectivity for HIV-
2[Env35] on GHOST/X4 cells as well (Fig. 5C). These
results together argue for enhanced endocytosis and
degradation of restricted particles, which encode for
glutamic acid at position 74 of the envelope protein. As
has been shown before, single point mutations in the outer
surface unit of the HIV-1 and SIVenvelope proteins result in
differences in viral infectivity and CD4 dependence (Otto et
S. Reuter et al. / Virology 332 (2005) 347–358354al., 2003) although these differences were correlated to
changes in the C3 region of the envelope protein. In
addition, coreceptor binding is modulated by single muta-
tions in the V3 loop and V1 loop, resulting for example in
the infection of target cells expressing low CCR5 (Boyd et
al., 1993; Clapham and McKnight, 2002; Dejucq et al.,
1999; Reeves et al., 2004). A correlation between CD4
binding capacity, due to a mutation(s) upstream of the V1
loop of HIV-2 gp125, and viral uptake has not been
described previously.
As has been described earlier, the ERK MAPK pathway
regulates infectivity of HIV-1 (Yang and Gabuzda, 1999)
and this pathway as well as the SAPK/JNK and p38-
MAPK pathways can by induced by HIV-1 gp120 binding
to target cells (Kinet et al., 2002; Popik and Pitha, 2000b)
and play a role in entry and post-entry events (Chackerian
et al., 1997). Therefore, we determined whether binding of
particles to target cells cause activation of different signal-
ling cascades, which could result in activation or inactiva-
tion of restriction factors leading to the restriction observed
or bypassing the restriction observed, respectively. The
activation of ERK, SAPK/JNK, or p38-MAPK signalling
cascades, however, did not differ after binding of restricted
envelope proteins compared to nonrestricted envelopes to
GHOST/X4 cells (Fig. 6). Recently, it has been described
that actin cytoskeleton rearrangement is important for virus-
induced cell fusion and dependent on coreceptor-mediated
activation of Rac, a downstream effector of Pyk2 (Pontow
et al., 2004). Whether the activation of other protein
kinases, like Pyk2, differ due to binding of restricted
particles compared to nonrestricted particles remains to be
shown.
With regard to the observed restriction to infection of
GHOST/X4 cells, we demonstrate that a large part of this
restriction is a direct consequence of tight CD4-binding and
subsequent endosomal uptake, perhaps leading to degrada-
tion of particles in the lysosome, and not a post-entry
restriction. However, even in the presence of 10 mM NH4Cl,
when endosomal acidification is blocked completely, we
observe a remaining restriction to infection (19 fold) for
particles carrying the restricted envelope protein Env35
compared to particles carrying the nonrestricted envelope
protein Env42S (Fig. 5D). These results are in agreement
with our previous finding using molecular clones of the two
isolated prCBL23 and CBL23 (Schmitz et al., 2004), where
the exchange of the entire envelope coding region of the
restricted clone MCR by the envelope coding region of the
nonrestricted clone MCN resulted in the reduction but not
abrogation of the restriction to infection. Therefore, it is
feasible that divergent entry pathways from distinct plasma
membrane structures are used by HIV-2[Env35] in compar-
ison to HIV-2[Env42S], as initially proposed (McKnight et
al., 2001; Schmitz et al., 2004). Such divergent entry
pathways could result in the delivery of the viral cores to
different cytosolic compartments where the concentration
and/or activity of restriction factors, like Lv2, differ. Inaddition, nuclear targeting of retroviral structures inside the
cell is dependent of intact cytoskeleton (Kizhatil and
Albritton, 1997; McDonald et al., 2002; Pontow et al.,
2004). Therefore, differences in microtubules or actin-
dependent movement could be the cause for the observed
restriction to infection. New methods to follow the fate of
retroviral structures in infected cells have been used
successfully (McDonald et al., 2002) and future studies
will address the localization of such structures inside the cell
and potential differences between restricted and nonres-
tricted infection, thereby defining the postulated permissive
cytosolic compartments. The existence of such permissive
and nonpermissive cytosolic compartments, which have or
have not access to the nucleus and bypass or overcome the
action of restriction factors, needs to be addressed in the
future.
In conclusion, we can show that a single point mutation
(G74E) in the restricted envelope protein Env35 causes
tighter CD4 binding on GHOST/X4 cells and enhanced
endocytosis resulting in a less efficient fusion into the
cytosol. The previously described restriction to infection of
the primary isolate prCBL23 (McKnight et al., 2001;
Schmitz et al., 2004) is therefore largely caused by an entry
defect. However, a remaining restriction to infection (19-
fold) is preserved when endosomal acidification is pre-
vented. This restriction to infection is also dependent on the
presence of the point mutation at position 74 (G74E) and
could, therefore, together with the capsid-dependent restric-
tion to infection, account for the Lv2-mediated restriction in
human cells. More studies are needed to address this Lv2-
dependent entry restriction.Materials and methods
Cells and pseudotyped viruses
U87/CD4 cells expressing the chemokine receptor
CXCR4 and GHOST-CXCR4 were provided by the EU
programme EVA/MRC centralized facility for AIDS
reagents, NIBSC, UK. HEK293T cells were used for
transfection with ROD-ADenv vectors and MP11-derived
env-expression plasmids using Fugene6 (Roche, Ger-
many). Virus containing supernatants were harvested 3
days later, filtered, and stored at 80 8C. Virus
production into the supernatant was quantified by meas-
urement of RT activity using a sensitive nonradioactive
method (Retrosys RT activity kit, Cavidi Tech, Uppsala,
Sweden).
Construction of ROD-ADenv vectors and envelope
expression plasmids
The vector ROD-ADenv was constructed using the
ROD-A molecular clone ACR23 as follows: The first
eight nucleotides of the env ORF have been deleted by
S. Reuter et al. / Virology 332 (2005) 347–358 355site-directed mutagenesis PCR with the oligomers EnvD8
(5V-CCGTCGTCTCC TACACCAGACAAGTGAGTT-
CAGCTGCTTATTGCC-3V) and ROD-A8581- (5V-GCGG-
CCTGGAATGCTTCTTGGATC-3V). The resulting PCR
fragment has been cloned into ACR23 via Esp3 (6129)
and BsmI (8581) to substitute the original sequence
(numbering according to published ROD-A sequence).
Recombinant PCR was also used to replace large parts of
the nef ORF by the coding region of the green fluorescent
protein (EGFP, Clonetech, Germany), monomeric RFP
(Campbell et al., 2002) and renilla luciferase, resulting in
ROD-ADenv-GFP, ROD-ADenv-RFP and ROD-ADenv-





and gfp (5V-TATATGCC ATGGTGATCAGTTATCTAG-
ATCCGGTGGATC-3V) were used to perform a recombinant
PCR. The corresponding NcoI–NcoI fragment of ACR23
was replaced by the fusion-PCR product encoding for EGFP
instead of NEF. Similarly, the mRFP and renilla luciferase
marker genes were introduced using specific primers to yield
ROD-ADenv-RFP and ROD-ADenv-REN.
To amplify the envelope sequences of prCBL23 and
CBL23 from molecular clones of these isolates, the
following primer pairs were used: 5V-GGATA AGTCGC-
GGCCGCATGATGGGTGGTAGAAATCAGCTGC-3V and
5V-GCCAGGGAA GCTTTCATAGGAGGGCGATCTCTG-
CTCCC-3Vcreating a NotI site at the 5Vend and a HindIII site
at the 3Vend. The PCR products were cloned into the
expression vector pMP11 (Schambach et al., 2000) to create
the plasmids Env35 and Env42. Env35R2 and Env42S were
constructed by exchanging the 3Vends of Env35 and Env42
via BstEII (2129) and HindIII (MCS of MP11) (numbering
according to the env-expression plasmid). The chimeric
envelope Env53S was created by exchanging the very N-
terminal part between Env35 and Env42S as indicated in
Fig. 1B using the restriction sites NotI (located within the
MP11 vector) and EcoRI (421). Single point mutation Envs
(Env42S–G74E,and Env35–E74G) were created by fusion
PCR thereby producing the exchanges G74E and E74G in
Env42S or Env35, respectively.
Immunostaining of HIV-2-infected cells and calculation of
restriction
The immunostaining method has been described before
(McKnight et al., 2001). Briefly, HIV-infected cells were
washed in serum-free phosphate-buffered saline (PBS) and
fixed in methanol/acetone, 1:1 at 20 8C. After washing in
PBS/1% FCS (PBS/FCS), HIV-2-positive serum was added
at 1/5000 (in PBS/FCS) to detect virus antigen. After three
washes in PBS/FCS, the cells were incubated for 1 h with
mouse anti-human IgG conjugated with h-galactosidase
(Southern Biotech). After a further three washes in serum-free PBS, 0.5 mg/ml X-gal substrate (Sigma, Germany) in
PBS containing 3 mM potassium ferricyanide, 3 mM
potassium ferrocyanide, and 1 mM magnesium chloride
was added. Clusters of blue cells were counted as foci of
infection (FFU) to estimate the viral titre. The restriction (n-
fold) is calculated as the ratio of infectivity of unrestricted
cells to restricted cells (ratio U87/CD/X4 vs. GHOST/X4
cells).
Viral entry assay
HIV-2 particles carrying a h-lactamase reporter protein
were produced by cotransfection of 293T cells with the
ROD-ADenv vector, an envelope expression vector and
pMM310-vpr2 (a derivative of pMM310), a construct
encoding h-lactamase (BlaM) fused to the amino terminus
of the virion protein vpr2 (BlaMDvpr2), thereby targeting
BlaM to the virion. U87/CD4/X4 cells (2  104 cells) or
GHOST/X4 cells (1  104 cells) in 96-well dishes (clear
bottom) were infected with h-lactamase-loaded virus at a
moi of 0.5 or higher. After 3 h, the cells were washed twice
with PBS and then loaded with 2 AM CCF2/AM/1%
probenecid in 50 Al of serum-free, CO2-independent
DMEM for 16–18 h at room temperature. The cells were
washed two times with medium and analyzed using a
microplate fluorometer (Safire, Tecan, Germany) after
excitation at 409 nm. Cleaved substrate was detected as
blue fluorescence at 447 nm, and uncleaved substrate was
detected as green fluorescence at 520 nm. Fusion of the HIV
reporter particles results in delivery of active BlaM into the
cytosol; thus, the ratio of blue to green fluorescence is
directly correlated with the efficiency of virus–cell fusion
(Wyma et al., 2004; Zhou et al., 2004).
CD4 binding and infectivity analysis
For the anti-CD4 antibody inhibition studies on U87/
CD4/X4 and GHOST/X4 cells, 3  104 cells per well (in a
48 well tray) were pre-treated for 30 min at 37 8C with
anti-CD4 antibody at different concentrations (5, 1, 0.2,
0.04, and 0.002 Ag of anti-CD4 antibody/ml; Clone RPA-
T4, Pharmingen, Germany) before adding equal amounts
of particles (5 ng RT-equivalent). The cells were lysed at 2
days post-infection and the renilla luciferase activity
(expressed due to infection with ROD-ADenv-REN
derived particles) was measured using the renilla luciferase
system (Promega, Germany) and a luminometer (Labsys-
tems, Germany). Duplicate wells were analyzed for each
drug concentration in at least three independent experi-
ments. Relative activity (% of control) was calculated by
dividing the mean number of relative light units at each
anti-CD4 antibody concentration by the mean number of
relative light units from cells containing no antibody. For
the analysis of particle-associated envelope protein medi-
ated binding to cell-associated CD4 in the absence of any
coreceptor, pseudotyped particles containing a mRFP:vpr2
S. Reuter et al. / Virology 332 (2005) 347–358356fusion protein were generated. Cotransfection of 293T cells
with the ROD-ADenv vector, an envelope expression
vector and pRFP-vpr2, a construct encoding mRFP fused
to the amino terminus of the virion protein vpr2
(mRFPDvpr2), thereby targeting mRFP into the virions,
resulting in infectious particles that can be monitored due
to their red fluorescence. After transfection of 293T cells
with the expression plasmid pSG5/CD4-cyt399 (Bedinger
et al., 1988; Maddon et al., 1988), which encodes for a
truncated CD4 molecule lacking the cytoplasmic tail
(CD4-cyt399), the cells were seeded into 96-well dishes
at 2  104 cells per well and incubated with the different
pseudotyped HIV-2 particles (25 ng RT-equivalent) for 1 h
at 37 8C/5% CO2. The binding of viral particles to CD4-
cyt399-expressing 293T cells in comparison to 293T cells
lacking CD4 was quantitated by excitation of mRFP (584
nm) and recording the emission at 607 nm using a
fluorometer (Safire).
Endocytosis of CD4
Basal endocytosis for CD4 expressed on the surface of
GHOST/X4 cells and U87/CD4/X4 cells was assayed as
described (Schwartz et al., 1996). Briefly, cells were
stained at 4 8C for CD4 (clone RPA-T4, BP Pharmingen)
in binding medium (BM: RPMI medium, 2% FBS, 20 mM
HEPES, pH7.2). Excess antibody was washed away and
cells resuspended in cold BM. Cell suspensions were
shifted to 37 8C, and, at time points between 0 and 60
min, aliquots were placed on ice. Noninternalized anti-
body-labeled CD4 were indirectly stained with R-phycoer-
ythrin-conjugated goat anti-mouse antibody (Jackson
ImmunoResearch). The endocytosis was assessed by
analyzing the decrease of MFI of CD4 staining on viable
cells in the course of the kinetic. Percentages of remaining
cell surface CD4 at different time points was calculated
and plotted over time.
Endosomal particle uptake
To prevent endosome formation, GHOST/X4 cells were
nucleofected with expression plasmids encoding for a
dynamin-GFP (dynGFP) fusion protein as well as a
dominant-negative version of dynamin (dynK44AGFP),
respectively (Cao et al., 1998; van der Bliek et al., 1993)
according to the manufacturer’s protocol (Amaxa, Ger-
many). Cells were seeded into 48-well trays and the next
day infected with ROD-ADenvRFP-derived pseudotyped
particles. Forty-eight hours post infection, the fluorescence
intensity at 607 nm (mRFP expressing, infected cells) and at
508 nm (nucleofected, GFP-fusion protein expressing cells)
was determined. The calculated ratio between these two
fluorescence intensities allows a quantification of effective
HIV-2 infection dependent on the expression of dominant-
negative dynamin versus the expression of wild-type
dynamin.For the inhibition of endosomal acidification, both cell
lines were pretreated with NH4Cl (10 mM) for 30 min at
37 8C before adding equal amounts of infectious virus
(ROD-ADenv-derived particles). The cells were immunos-
tained 2 days post infection and the number of blue cells
determined. HIV-2[VSV-G] particles were used to control
for complete inhibition of acidification of endosomes.
Stimulation of MAPK family members through particle
binding
Prior to stimulation, GHOST/X4 cells were maintained
for 48 h in DMEM with 0.1% FCS. Cells were incubated
with particle preparations (100 ng RT equivalents) carrying
no envelope, Env35, Env42S, 200 ng/ml anisomycin
(Sigma) or 10% FCS in the presence or absence of 50 AM
UO126 (Cell Signaling Technology, Germany) for 30 min at
37 8C. Cells were washed two times in PBS and lysed in
SDS sample buffer. For Western blot analysis, samples were
boiled in SDS sample buffer, separated by SDS-10% PAGE,
and transferred to a nitrocellulose membrane. Protein
detection was performed after incubation with appropriate
first and secondary antibodies (Phospho-MAPK family
antibody sampler, Cell Signaling Technologies, Germany)
by using the Super-Signal Pico detection kit (Pierce, Bonn,
Germany) according to the manufacturer’s instructions. The
detection of 14-3-3g (loading control) was performed using
the polyclonal antibody C-16 (Santa Cruz, Germany) as
primary antibody.Acknowledgments
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